TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The conjugated repeating units comprise: optionally substituted thiophene units; or phenylene units, carbazole units, fluorene units, pyrrole units, furan units and/or triazolothiazole units (all optionally substituted). The acceptor units comprise: at least one derivative of thiadiazoloquinoxaline, quinoxaline, thienothiadiazole, thienopyrazine, pyrazinoquinoxaline, benzothiadiazole (preferably 2,1,3-benzothiadiazole), bis-benzothiadiazole, thiadiazolothienopyrazine (all preferred) and/or benzotriazole.    TECHNOLOGY FOCUS - POLYMERS - Preparation (Claimed): Preparation of fDA-CP comprises: providing to a polymerization mixture comprising many or at least one fDA-oligomer comprising at least one isolated acceptor unit comprising an electron poor aromatic moiety flanked by fused donor units, where at least one fused donor unit resides at each termini of the fDA-oligomer; and polymerizing the polymerization mixture chemically. Preferred Components: The fused donor units: comprise fused polycyclic compounds of formula (I); and are present in even numbered monodispersed sequences between acceptor repeating units. The fDA-CP comprises bis(fused polycyclic compounds) of formula (II), (III) or (IV). The fDA-CP further comprises at least one conjugated aromatic units between the fused donor units. The fDA-oligomer comprises: bis(fused polycyclic) compounds of formula (V), (VI), (VII) or (VIII). The polymerization mixture further comprises a monomer or oligomer comprising at least one conjugated aromatic unit, where in the polymerizing step, the polymerization mixture results in the conjugated aromatic units separated from the acceptor units by the fused donor repeating units of the fDA-oligomer.E = -CH=CH-, S, Se, NH, NR or Si;X = C, Si or N;R = 1-24C alkyl, 1-10Si (silane or siloxane) (substituted with H, CH3, 2-6C alkyl, aryl or other solubilizing group) or 2-24C alkylenyl (all optionally branched);A = acceptor unit comprising electron poor aromatic moiety, preferably benzo(c)(1,2,5)thiadiazole, where the monomer or oligomer comprising at least one conjugated repeating unit is 2,5-bis(trimethylstannyl)thiophene moiety of formula (a) or (9,9-dimethyl-9H-fluoren-2,7-diyl)bis(trimethylstannane) moiety of formula (b);m, x = 1-5;p = 0 or 1; andn = 5-10000. EXAMPLE - 5-Trimethylstannyl-3,3'-di-(2-ethylhexyl)silylene-2,2'-bithiophene (1.70 g), 4,7- dibromobenzo(c)(1,2,5)-thiadiazole (0.43 g), tris(dibenzylideneacetone)dipalladium(0) (26 mg) and P(o-tol)3 (35 mg), were charged in 250 ml flask, and evacuated and backfilled with argon 4 times, then toluene (150 ml) was added. The mixture was heated at 80 degrees C overnight. The reaction mixture was worked up to give 4-(7,7-dioctyl-3,11-dithia-7-silatricyclo(6.3.0.0(2,6))undeca-1(8),2(6),4,9-tetraen-4-yl)-7-(7-heptyl-7-octyl-3,11-dithia-7-silatricyclo(6.3.0.0(2,6))undeca-1(8),2(6),4,9-tetraen-4-yl)-2,1,3-benzothiadiazole (A). To a solution of (A) (1.63 g) in chloroform (75 ml) which was cooled to 0 degrees C, and added a solution of N-bromosuccimide (0.598 g) in methylcyanide (50 ml) for 40 minutes, and stirred another for 1 hour at 0 degrees C and then poured into water (100 ml). And the reaction mixture was worked up to give an intermediate (B). Then (A) (415 mg) was dissolved in chloroform (50 ml). Solution of anhydrous ferric chloride (347 mg) in nitromethane was added dropwise for 30 minutes to the stirred monomer and the mixture was stirred overnight, and then precipitated into methanol (200 ml). And the reaction mixture was worked up and then the polymer was extracted with chloroform, concentrated by evaporation, and precipitated in methanol (200 ml) to give 4-(7,7-dioctyl-3,11-dithia-7-silatricyclo(6.3.0.0(2,6))undeca-1(8),2(6),4,9-tetraen-4-yl)-7-(7-heptyl-7-octyl-3,11-dithia-7-silatricyclo(6.3.0.0(2,6))undeca-1(8),2(6),4,9-tetraen-4-yl)-2,1,3-benzothiadiazole polymer.